T2 Biosystems (NASDAQ:TTOO) and Repro-Med Systems (OTCMKTS:REPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
This is a breakdown of recent recommendations for T2 Biosystems and Repro-Med Systems, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares T2 Biosystems and Repro-Med Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
49.7% of T2 Biosystems shares are owned by institutional investors. Comparatively, 17.8% of Repro-Med Systems shares are owned by institutional investors. 31.5% of T2 Biosystems shares are owned by insiders. Comparatively, 40.0% of Repro-Med Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares T2 Biosystems and Repro-Med Systems’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|T2 Biosystems||$10.50 million||10.64||-$51.15 million||($1.26)||-2.00|
|Repro-Med Systems||$17.35 million||3.52||$910,000.00||N/A||N/A|
Repro-Med Systems has higher revenue and earnings than T2 Biosystems.
Volatility & Risk
T2 Biosystems has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Repro-Med Systems has a beta of -0.8, suggesting that its stock price is 180% less volatile than the S&P 500.
Repro-Med Systems beats T2 Biosystems on 6 of the 11 factors compared between the two stocks.
About T2 Biosystems
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
About Repro-Med Systems
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.